or Try an Advanced Search...

    Technical Analysis for RNAZ - TransCode Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.96 -4.54% -0.05
    RNAZ closed down 4.54 percent on Monday, July 1, 2024, on 11 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical RNAZ trend table...
    Date Alert Name Type % Chg
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Hammer Candlestick Bullish -4.54%
    Lizard Bullish Bullish Day Trade Setup -4.54%
    Doji - Bullish? Reversal -4.54%
    Wide Bands Range Expansion -4.54%
    Older End-of-Day Signals for RNAZ ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 9 hours ago
    Down 1% about 9 hours ago
    Down 5% 3 days ago
    Down 3% 3 days ago
    Fell Below Previous Day's Low 3 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    RNAZ Chart by TradingView
    Basic chart:

    Profile

    TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Preclinical Stage Product Metastatic Cancer

    Is RNAZ a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 10 TransCode Therapeutics regains compliance with Nasdaq
    Jun 10 Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
    May 29 TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
    May 13 Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered
    May 13 TransCode Therapeutics Open Letter to Shareholders
    Apr 15 TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
    Apr 3 TransCode Therapeutics reports FY results
    Apr 3 TransCode Therapeutics Reports 2023 Results; Provides Business Update
    Mar 28 TransCode Therapeutics appoints Vlock as chief medical officer
    Mar 28 TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
    See more RNAZ news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 128.0
    52 Week Low 0.42
    Average Volume 1,507,392
    200-Day Moving Average 6.49
    50-Day Moving Average 1.06
    20-Day Moving Average 1.15
    10-Day Moving Average 1.02
    Average True Range 0.16
    RSI (14) 43.50
    ADX 22.46
    +DI 18.87
    -DI 30.64
    Chandelier Exit (Long, 3 ATRs) 1.32
    Chandelier Exit (Short, 3 ATRs) 1.38
    Upper Bollinger Bands 1.48
    Lower Bollinger Band 0.81
    Percent B (%b) 0.22
    BandWidth 58.11
    MACD Line -0.05
    MACD Signal Line -0.02
    MACD Histogram -0.0334
    Fundamentals Value
    Market Cap 1.01 Million
    Num Shares 1.06 Million
    EPS -652.00
    Price-to-Earnings (P/E) Ratio 0.00
    Price-to-Sales 0.00
    Price-to-Book 0.16
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.05
    Resistance 3 (R3) 1.05 1.03 1.03
    Resistance 2 (R2) 1.03 1.00 1.02 1.03
    Resistance 1 (R1) 0.99 0.99 0.98 0.99 1.02
    Pivot Point 0.97 0.97 0.96 0.96 0.97
    Support 1 (S1) 0.93 0.94 0.92 0.93 0.89
    Support 2 (S2) 0.91 0.93 0.91 0.89
    Support 3 (S3) 0.87 0.91 0.89
    Support 4 (S4) 0.87